ArticleResearch and practice in thrombosis and haemostasis2026
Assessing the efficacy of a single-cycle measurement and adjustment strategy for direct oral anticoagulants in frail older patients: rationale and design of the DOAC-FRAIL randomized controlled trial.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frail older patients are at high risk of both thromboembolism and bleeding, making anticoagulant therapy challenging. Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists because of comparable efficacy and lower bleeding risk. However, evidence supporting their use in frail older patients remains limited. Recent studies have demonstrated that a substantial proportion of frail older patients have DOAC plasma levels outside the expected on-therapy range, which may be associated with an increased risk of bleeding or thromboembolic events. Objectives: The DOAC-FRAIL randomized controlled trial (RCT) aims to determine whether adjustment of DOAC therapy based on peak plasma concentrations improves the safety and efficacy of anticoagulant treatment compared with standard care in frail older patients. Methods: The DOAC-FRAIL study is an international, multicenter, randomized controlled trial including frail older patients aged ≥70 years with a Clinical Frailty Scale score >3 receiving DOAC therapy. Participants are randomized to either a Single Cycle Measurement and Adjustment Strategy based on peak DOAC plasma concentrations or standard care. Patients with a life expectancy of less than 3 months or previous DOAC dose adjustment based on plasma level measurements are excluded. The primary outcome is the composite of bleeding events, including clinically relevant non-major bleeding, and thromboembolic events during 2 years of follow-up. Secondary outcomes include feasibility, determinants of deviant peak DOAC plasma concentrations, quality of life, cost-effectiveness, and all-cause mortality. Results: The DOAC-FRAIL trial is currently ongoing. Participant recruitment has been initiated, and study results are expected after completion of follow-up. Conclusion: The DOAC-FRAIL RCT will provide evidence on whether a plasma concentration-guided DOAC dosing strategy improves clinical outcomes compared with standard care in frail older patients. The findings may contribute to more personalized anticoagulant therapy in this vulnerable population. Trial registration number: EU CT-2025-521362-10-00.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.